Enzo Life Sciences, CGI Sign Supply and Distridution Agreement
This agreement covers Enzo’s proprietary fluorescent dye labels for increasing signal intensity in labeling nucleic acids.
The non-exclusive agreement enables Enzo Life Sciences to incorporate its proprietary labeling to increase specificity for CGI’s nucleic acid material that it purchases and supplies to the research market. The Enzo labeling in essence affords the CGI probe greater visual sensitivity and the potential for improved clinical value and patient outcomes.
Carl Balezentis, president of Enzo Life Sciences, said: “We are pleased to be able to enter into a collaborative agreement with CGI which leverages the strengths of both companies. CGI is developing unique content in the areas of FISH and micro arrays, while we offer unique manufacturing capabilities in both of these areas.
“Specifically, this agreement enables us to offer our labeling products in conjunction with CGI's FISH probes, which are highly regarded in the research market, and which also provide strong recognition for our technology. We also recognize that opportunities exist to expand our clinical lab offerings through the unique products and services for personalized cancer treatment being offered and being developed by CGI.”
RSK Chaganti, founder and chairman of CGI, said: “This agreement will introduce the next generation of innovation and sensitivity in DNA probes being used for clinical cytogenetics for oncology.”
Will the firms benefit with the agreement?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.